CN107629077A - Azole derivatives of Gefitinib fluorine boron two of acid-sensitive and preparation method thereof and application in medicine - Google Patents
Azole derivatives of Gefitinib fluorine boron two of acid-sensitive and preparation method thereof and application in medicine Download PDFInfo
- Publication number
- CN107629077A CN107629077A CN201710872025.4A CN201710872025A CN107629077A CN 107629077 A CN107629077 A CN 107629077A CN 201710872025 A CN201710872025 A CN 201710872025A CN 107629077 A CN107629077 A CN 107629077A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- gefitinib
- formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 150000007980 azole derivatives Chemical class 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 title abstract description 8
- 229960002584 gefitinib Drugs 0.000 title abstract description 8
- LIQLLTGUOSHGKY-UHFFFAOYSA-N [B].[F] Chemical compound [B].[F] LIQLLTGUOSHGKY-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 201000011510 cancer Diseases 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 208000024519 eye neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 17
- 239000003795 chemical substances by application Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 229910052796 boron Inorganic materials 0.000 abstract description 10
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052731 fluorine Inorganic materials 0.000 abstract description 9
- 239000011737 fluorine Substances 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 230000003287 optical effect Effects 0.000 abstract description 8
- 230000007062 hydrolysis Effects 0.000 abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 5
- 230000001235 sensitizing effect Effects 0.000 abstract description 5
- 238000002965 ELISA Methods 0.000 abstract description 4
- 150000004924 Gefitinib derivatives Chemical class 0.000 abstract description 3
- 238000011275 oncology therapy Methods 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 101710147108 Tyrosinase inhibitor Proteins 0.000 abstract description 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 235000013350 formula milk Nutrition 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- -1 p-methyl benzenesulfonic acid acyl chlorides Chemical class 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000001531 bladder carcinoma Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- OBSLWIKITOYASJ-AZEWMMITSA-N (2r,3s,4s,5r,6s)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical compound CN[C@@H]1[C@H](O)O[C@@H](CO)[C@H](O)[C@H]1O OBSLWIKITOYASJ-AZEWMMITSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000417413 Gentiana cephalantha Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DDFGTVSLZJLQEV-UHFFFAOYSA-N [C](C1CCCCC1)C1CCCCC1 Chemical compound [C](C1CCCCC1)C1CCCCC1 DDFGTVSLZJLQEV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical group N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Azole derivatives of Gefitinib fluorine boron two connected the present invention relates to the ketal of slightly sour environment sensitive and preparation method thereof and application in medicine, the molecular structural formula of the derivative is as described in (I) formula in specification.Especially, azole derivatives of Gefitinib fluorine boron two of the present invention and preparation method thereof and the pharmaceutical composition containing the compound, as well as the purposes of sensitising agent, the purposes particularly in treating cancer.The influencing each other due to Gefitinib group and the azole derivatives of fluorine boron two under normal structure environment, the compound has relatively low cytotoxicity, but outside tumor tissue cell under slightly sour environment, hydrolysis occurs for ketal, hydrolyze the obtained azole derivatives fragment of fluorine boron two and show high photosensitive activity, and EGF-R ELISA (EGFR) tyrosinase inhibitor can be used as by hydrolyzing obtained Gefitinib derivative, suppress tumour growth.They can be prepared into the optical dynamic therapy and the double curative effect cancer therapy drugs of chemotherapy of the double targetings of slightly sour environment and EGFR EGFR-TK outside tumour cell.
Description
Technical field
The invention belongs to field of medicaments, is related to Gefitinib-azole derivatives of fluorine boron two and preparation method thereof and its is curing
Application on medicine, the invention discloses it as the double curative effect medicines of optical dynamic therapy-chemotherapy, the purposes for treating cancer.
Technical background
Optical dynamic therapy (Photodynamic Therapy, abbreviation PDT), also known as photoradiation therapy
(Photoradiation Therapy, abbreviation PRT) or photochemotherapy (Photochemotherapy), are that one kind is based on
The treatment method of the photochemical reaction principle of particular chemicals.Chemical substance used be referred to as tumour chemistry diagnosis and treatment medicine (
Claim sensitising agent, Photosensitizer, abbreviation PS).PDT therapy processes be by be injected intravenously sensitising agent is injected in vivo it is (right
Affected part can also be applied in skin), the light irradiation tumor tissues of specific wavelength are used after certain time, are enriched in tumour
The sensitising agent of tissue produces a series of optical physics chemical reactions under the exciting of light, the active oxygen of cytotoxicity is produced, so as to kill
Dead cancer cell destruction tumor tissues.
Clinic is approved by the fda in the United States within 1996, FDA in 1997 is included in five class basic skills of oncotherapy
One of (operation, radiotherapy, chemotherapy, light power, biochemical immunity).Compared with traditional therapy, PDT therapies have wound very little, poison
Property it is humble, selectivity is good, applicability is good, repeatable treatment, can palliative treatment, operation can be cooperateed with to improve curative effect, recessiveness can be eliminated
Carninomatosis stove, the advantage such as appearance and vitals function, treatment time can be protected short.Photodynamic therapy has been successfully applied to lung at present
Cancer, stomach cancer, the cancer of the esophagus, breast cancer, carcinoma of urinary bladder, prostate cancer, cancer of pancreas, cholangiocarcinoma, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, neck
The treatment of portion's cancer, Eye tumor, uterine cancer and oophoroma.
In recent years with EGF-R ELISA (epidermal growth factor receptor, EGFR) target spot
Cancer therapy drug is increasingly by concern.EGFR is a kind of membrane receptor, in Several Kinds of Malignancy such as neurogliocytoma, mammary gland
Have in cancer, lung cancer, oophoroma, G. cephalantha, cervical carcinoma, the cancer of the esophagus, prostate cancer, liver cancer, colon cancer, stomach cancer etc. excessively
Expression, activation EGFR can accelerate tumour cell breeding, promote Tumor Angiongesis, accelerate metastases, hinder tumor death.
A kind of EGFR tyrosine kinase inhibitors of Gefitinib, it is a kind of targeted drug for treating tumour.2002 first
Listed in Japan, be approved in May, 2003 to be used for Advanced Non-Small Cell as three line single therapy medicines in the U.S. and Australia
Lung cancer.Formally clinical treatment Locally Advanced or Metastatic Nsclc are had been used in Discussion on Chinese Listed within 2005.
Micro-environmental hypoxia existing for tumor entity tissue site causes the extracellular pH value of the region tumors relatively low (6.5
Left and right), and the outer pH value of normal tissue cell is 7.4 or so.PH value difference between tumor entity tissue and normal structure is swollen
The design of knurl targeted drug provides new strategy.
The invention discloses it is a series of by tumor tissue cell outside slightly sour environment sensitive key connection Gefitinib-fluorine
The azole derivatives of boron two.Due to the azole derivatives group of fluorine boron two and the mutual shadow of Gefitinib group under normal structure environment
Ring, the compound has relatively low cytotoxicity, but outside tumor tissue cell under slightly sour environment, can discharge pole simultaneously by hydrolysis
High photosensitive activity boron Asia phthalocyanine fragment point and high EGFR tyrosine-kinases enzyme inhibition activity Gefitinib derivative fragment.They can
It is prepared into the optical dynamic therapy and the double curative effect anticarcinogens of chemotherapy of the double targetings of slightly sour environment and EGFR EGFR-TK outside tumour cell
Thing.
The content of the invention
Gefitinib-the azole derivatives of fluorine boron two connected the present invention relates to the ketal of slightly sour environment sensitive and its preparation side
Method and application in medicine.Especially, Gefitinib of the present invention-azole derivatives of fluorine boron two and preparation method thereof and
Pharmaceutical composition containing the compound, as well as the purposes of sensitising agent, the purposes particularly in treating cancer.Just
Influencing each other due to Gefitinib group and the azole derivatives of fluorine boron two under normal organizational environment, the compound has relatively low cell
Toxicity, but outside tumor tissue cell under slightly sour environment, hydrolysis occurs for ketal, hydrolyzes the obtained azole derivatives of fluorine boron two
Fragment shows high photosensitive activity, and EGF-R ELISA can be used as by hydrolyzing obtained Gefitinib derivative
(EGFR) tyrosinase inhibitor, tumour growth is suppressed.They can be prepared into slightly sour environment and EGFR tyrosine outside tumour cell
The optical dynamic therapy and the double curative effect cancer therapy drugs of chemotherapy of the double targetings of kinases.
Compound shown in formula (I) provided by the invention：
Or its pharmaceutically acceptable salt.
Hydrolysis chemical formula (1) of the compound under the slightly sour environment of tumor tissues shown in logical formula (I)
PH value is that formula (I) compound structure is stable under 7.4 environment outside normal tissue cell.Due to the pyrrole derivatives of fluorine boron two
Thing group and Gefitinib group influence each other, and the complex has relatively low cytotoxicity.
But under relatively low (6.5 or so) environment of pH value outside tumor tissue cell, ketal key is unstable, lead to formula (I) energy
Hydrolysis obtains formula (II) and formula (III) compound.The compound structure of the structure of logical formula (II) compound and existing document report
Identical and similar (Jiang,X.-J.Et.al, Chem.Eur.J.2016,22,8273-8281), these compounds are thin in tumour
Born of the same parents' uptake ratio is high, shows very high photosensitive activity at very low concentrations.And formula (III) compound is and Gefitinib structure
Extremely similar compound, EGF-R ELISA TYR kinase inhibitory activity can be showed, suppress tumour growth.
The present invention also provides a kind of method for preparing the compound shown in formula (I), and reaction equation is as follows, but is not limited only to
Following method:
1st step, the organic solvent be selected from DMF, dimethyl sulfoxide (DMSO), dichloromethane, chloroform and
Tetrahydrofuran；The reaction is carried out at a temperature of -5~80 DEG C；The alkalescence condition by selected from pyridine, triethylamine, sodium hydride and
At least one of 4-N, N- lutidines reagent provides；The mol ratio of the material a and p-methyl benzenesulfonic acid acyl chlorides is 1:
0.2~2.
2nd step, the solvent are selected from DMF, dimethyl sulfoxide (DMSO), ethanol, methanol；The reaction is 30
Carried out at a temperature of~120 DEG C；The alkalescence condition is by selected from least one of pyridine, triethylamine, potassium carbonate, sodium carbonate reagent
There is provided；The intermediate a and material b mol ratio is 1:0.3~3.Material b bibliography method is held by raw material of Gefitinib
It is easily-synthesized to obtain (Tetrhedron Letters, 46 (43), 7381-7384).
3rd step, the solvent are selected from DMF, dimethyl sulfoxide (DMSO), dichloromethane, chloroform and tetrahydrochysene
Furans；Described catalyst is from triethylamine, pyridine, N, N- lutidines；The condensing agent is sub- from dicyclohexyl carbon two
Amine, DIC, 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides, 1- ethyls-(3- dimethylaminos third
Base) phosphinylidyne diimmonium salt hydrochlorate, O- (7- azepine BTA -1- bases)-two (dimethylamino) carbon hexafluorophosphates, O-
(BTA -1- bases)-two (dimethylamino) carbon hexafluorophosphate, O- (BTA -1- bases)-two (dimethylamino)
At least one of carbon tetrafluoroborate, (dimethylamino) the carbon tetrafluoroborates of O- (N- succimides base)-two；With/
Or the condensation activator is sub- from 1- hydroxy benzo triazoles, 1- hydroxyl -7- azos BTA, N- hydroxysuccinimidyls acyl
One kind in amine, HP；The reaction is carried out at a temperature of -5~80 DEG C；The logical formula (IV) chemical combination
Thing and intermediate c mol ratio are 1:0.4~4；Logical formula (IV) compound and the mol ratio of condensing agent are 1:0.4~4.Formula (IV)
Compound bibliography method synthesize to obtain (Jiang,X.-J.et.al,Chem.Eur.J.2016,22,8273–8281)。
If it is necessary, by method well known to those skilled in the art, such as by distillation, by silica gel column chromatography or
Person can also purifying compound by high performance liquid chromatography (HPLC).
The present invention also provides a kind of pharmaceutical composition, its contain compound shown in the formula of therapeutically effective amount (I) or or its
Pharmaceutically acceptable salt, and pharmaceutically acceptable carrier, diluent or excipient.
The invention further relates to the compound shown in formula (I) or its pharmaceutically acceptable salt, or include its drug regimen
Purposes of the thing in photo-dynamical medicine or photosensitive drug is prepared.
The invention further relates to the compound shown in formula (I) or its pharmaceutically acceptable salt, or include its drug regimen
Purposes of the thing in the medicine for preparing treating cancer.Wherein described cancer be selected from wherein described cancer be selected from lung cancer, stomach cancer,
The cancer of the esophagus, breast cancer, carcinoma of urinary bladder, prostate cancer, cancer of pancreas, cholangiocarcinoma, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, incidence cancer,
Eye tumor, uterine cancer and oophoroma.
The invention further relates to the compound shown in formula (I) or its pharmaceutically acceptable salt, or include its drug regimen
Thing, it is used as photo-dynamical medicine or photosensitive drug.
The invention further relates to the compound shown in formula (I) or its pharmaceutically acceptable salt, or include its drug regimen
Thing, it is used for treating cancer.Wherein described cancer be selected from lung cancer, stomach cancer, the cancer of the esophagus, breast cancer, carcinoma of urinary bladder, prostate cancer,
Cancer of pancreas, cholangiocarcinoma, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, incidence cancer, Eye tumor, uterine cancer and oophoroma.
The invention further relates to a kind of method for the treatment of cancer, and it includes giving formula (I) institute of required bacterium
The compound shown or its pharmaceutically acceptable salt, or its pharmaceutical composition is included, then irradiated with suitable light source.It is described
Suitable light source can be connected suitable optical filter to provide or be provided by the laser of specific wavelength by ordinary light source, light source
Wave-length coverage is 500~900nm, preferably 550~750nm.
It can be administered orally, sublingual administration, parenteral administration, subcutaneous administration, intramuscular applied according to the compound of the present invention
With, intravenous administration, applied dermally, local application or rectal administration.
In the medicinal compound of the present invention, for orally administering, sublingual administration, parenteral administration, subcutaneous administration, intramuscular
Using, for intravenous administrations, applied dermally, local application or rectal administration, active component can be with conventional pharmaceutical carrier
Mix, animals or humans is applied in the form of applying unit.Suitable unit form of applying includes oral form such as
Tablet, gel capsule, pulvis, granule and oral solution or supensoid agent, sublingual or oral administration form, parenteral,
Subcutaneously, intramuscular, intravenous, intranasal or intraocular administration form and rectal administration form.
When solid composite is prepared to tablet form, main active and pharmaceutical carrier such as gelatin, starch, breast
Sugar, magnesium stearate, talcum, Arabic gum etc. mix.Tablet can use sucrose or other suitable material coatings or with such as
This mode is handled so that it has active component that is extending or delay active and continuously discharging scheduled volume.
The mixture of acquisition is poured into soft or hard capsules by the way that active component and diluent are mixed into merga pass
To obtain gel capsule preparation.
The preparation of syrup or tincture form can include active component together with sweetener, preservative and aromatic and fit
When colouring agent.
The pulvis or granule being dispersed among in water can include active component, itself and dispersant, surfactant, wetting
Agent or suspending agent and mixed with flavouring or sweetener.Contain Emulsifier EL-60 in its drug regimen and its spread out
Biology, dimethyl sulfoxide, ethanol, glycerine, DMF, Liquid Macrogol -3000, cyclodextrin, glucose, tween,
One or more in polyethylene glycol mono stearate.
Suppository is used for rectal administration, and it uses the adhesive melted under rectal temperature, for example, cocoa butter or polyethylene glycol
To prepare.
(it includes pharmacology for aqueous suspension, isotonic normal saline solution agent or sterile and injectable solution
Upper compatible dispersant and/or wetting agent) it is used for parenteral, the administration of intranasal or intraocular.Contain polyoxy second in its drug regimen
Alkene castor oil and its derivative, dimethyl sulfoxide, ethanol, glycerine, DMF, Liquid Macrogol -3000, ring paste
One or more in essence, glucose, tween, polyethylene glycol mono stearate.
Active component (may be together with one or more additive carriers) can also be formulated into microcapsules.
The compound of the present invention can be used with the dosage between 0.01mg/ days and 5000mg/ days, with single dose
The mode in amount/day is provided or applied in a manner of some dosage in whole day, for example, same dose is twice daily.Applied
Daily dose is advantageously between 0.1mg and 200mg, or even more advantageously between 2.5mg and 50mg.Using beyond
The dosage of these scopes is probably needs, and those skilled in the art itself will be appreciated that this point.
In the particular of the present invention, pharmaceutical composition can also be formulated for external application.It can
To be introduced in the common type (that is, particularly lotion, foaming agent, gel, dispersant, spray) that this applies type,
The common type has excipient, and the excipient is particularly capable of penetrating skin, in order to improve the property of active component
And accessibility.In addition to the composition according to the present invention, these compositions are generally further comprising physiologically acceptable
Medium, the medium generally comprise water or solvent, for example, alcohol, ether or ethylene glycol.The composition can also include surface-active
It is agent, preservative, stabilizer, emulsifying agent, thickener, the other active components for producing complementary effect or possible synergy, micro-
Secondary element, essential oil, spices, colouring agent, collagen, chemistry or mineral filtering agent.
Definition
Unless stated to the contrary, it is otherwise following that there are following implications with term in the specification and in the claims.
In the present invention, " pharmaceutically acceptable " is understood to mean it and is used to prepare pharmaceutical composition, the combination
Thing is usually safety, nontoxic, meets needs in terms of biology or other and the composition can be acceptable for
Beasts and human pharmaceutical use.
In the present invention, " pharmaceutically acceptable salt " of compound is understood to refer to following salt, and it is pharmaceutically may be used
Receive (as herein defined) salt and it possess the pharmacological activity of expected parent compound.This salt includes：
(1) with the acid-addition salts of the inorganic acid such as formation such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or with organic acid such as
Acetic acid, benzene sulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethyl sulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, ethanol
Acid, hydroxyl naphthoic acid, 2- ethylenehydrinsulfonic acids, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2- naphthalene sulfonic acids, propionic acid,
The formation such as salicylic acid, butanedioic acid, dibenzoyl-L-tartaric, tartaric acid, p-methyl benzenesulfonic acid, trimethylace tonitric, trifluoroacetic acid
Acid-addition salts；With
(2) the sour proton present in the parent compound is by metal ion, for example, alkali metal ion is (for example, Na+、K+Or
Li+), alkaline-earth metal ions (such as Ca2+Or Mg2+) or aluminium ion replacement；Or the salt formed when being coordinated with organic base or inorganic base.
Acceptable organic base includes diethanol amine, monoethanolamine, N-METHYL-ALPHA-L-GLUCOSAMINE, triethanolamine, tromethamine etc..Acceptable nothing
Machine alkali includes aluminium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
" pharmaceutical composition " represent containing one or more compounds described herein or its physiologically/pharmaceutically useful salt or
Pro-drug and the mixture of other chemical constituents, and other components such as physiology/pharmaceutically useful carrier and excipient.Medicine
The purpose of compositions is to promote the administration to organism, the absorption beneficial to active component and then performance bioactivity.
" Ts " is p-methyl benzenesulfonic acid base.
" TsCl " is p-methyl benzenesulfonic acid acyl chlorides.
Embodiment
By reading the following example, those skilled in the art will be better understood the present invention.These embodiments are only used
It is of the invention in explaining.
The experimental method of unreceipted actual conditions in the embodiment of the present invention, generally according to normal condition, or according to raw material or
Condition proposed by commodity manufacturer.The reagent in unreceipted specific source, for the conventional reagent of market purchase.Material b is referred to
Literature method is easy to synthesis as raw material using Gefitinib and obtained (Tetrhedron Letters, 46 (43), 7381-7384).
Formula (IV) compound bibliography method synthesize to obtain (Jiang,X.-J.et.al,Chem.Eur.J.2016,22,8273–
8281)。
NMR:Bruker ARX-400 type high-resolution high resolution NMR instrument.
Mass spectrum：QSTAR Elite series connection level Four bar time of-flight mass spectrometers.
MTT detecting instruments：Thermo Scientific Multiskan GO all-wave length ELIASAs.
PBS：Phosphate buffer.
The structure of compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrum (MS).Nmr chemical displacement (δ) with
10-6(ppm) unit provides.Measure solvent is deuterated dimethyl sulfoxide (DMSO-d6), inside it is designated as tetramethylsilane (TMS).Use
Following abbreviations：S is unimodal, and bs is width unimodal, and d is doublet, and t is triplet, and qdt is quartet, and m is multiplet or a large amount of
Peak, dd are double doublet etc..
Tlc silica gel plate uses Qingdao GF254 silica gel plates, the rule that the silica gel plate that thin-layered chromatography (TLC) uses uses
Lattice are 0.15mm~0.2mm, and the specification that thin-layer chromatography isolates and purifies product use is 0.4mm~0.5mm.
Column chromatography is carrier typically using the mesh silica gel of Yantai Huanghai Sea silica gel 200~300.
In embodiment unless otherwise specified, reaction is carried out under argon atmospher or blanket of nitrogen.
In embodiment unless otherwise specified, the solution in reaction refers to the aqueous solution.
In embodiment unless otherwise specified, the temperature of reaction is room temperature.
The monitoring of reaction process in embodiment uses thin-layered chromatography (TLC).
Embodiment 1：The synthesis of formula (I) compound
1st step
In ice-water bath, material a (1.64g, 10mmol), p-methyl benzenesulfonic acid acyl chlorides (1.9g, 10mmol) and pyridine
(1.6g, 20.2mmol) adds dichloromethane (45mL), and temperature is raised to room temperature, continues stirring reaction 15 hours, stops reaction, to
Water (300mL) is added in reaction solution, stirring is stood, and is collected organic phase, organic phase anhydrous sodium sulfate drying, is evaporated under reduced pressure, slightly
Product silica gel column chromatography column separating purification, eluant, eluent are methylene chloride/methanol (10:1) it is intermediate a, to obtain white oil thing
(1.79g, 56%).MS(ESI):M/z=319 [M+H]+。
2nd step
In ice-water bath, intermediate a (1.59g, 5mmol), material b (2.16g, 5mmol) adds N, N- dimethyl methyls
Acid amides (50mL), Anhydrous potassium carbonate (1.38g, 10mmol) is added into reaction solution, reaction solution is heated to 90 DEG C, stirring reaction 15
Stop reaction after hour.Decompression removes organic solvent after reaction stops, and crude product adds dichloromethane 100mL stirring and dissolvings, then
Water 200mL stirring is added, organic phase is collected after standing and with anhydrous sodium sulfate drying, vacuum distillation, crude product silica gel column chromatography
Column separating purification, eluant, eluent are methylene chloride/methanol (15:1) it is intermediate c (1.82g, 62%), to obtain brown solid.1H
NMR(400MHz,DMSO-d6):δ 9.50 (s, 1H, NH), 8.50 (s, 1H, Ar-H), 8.08-8.15 (m, 1H, Ar-H), 7.70-
7.83 (m, 2H, Ar-H), 7.38-7.49 (m, 1H, Ar-H), 7.20 (s, 1H, Ar-H), 4.10-4.26 (m, 4H, CH2),
3.55-3.72(m,10H,CH2),2.44-2.55(m,2H,CH2),2.34-2.45(m,4H,CH2),1.94-2.05(m,2H,
CH2),1.41(s,6H,CH3).MS(ESI):M/z=579 [M]+。
3rd step
Formula (IV) compound (1.06g, 1.0mmol) and intermediate c (0.64g, 2mmol) are dissolved in N, N- dimethyl methyls
Acid amides (30mL), solution temperature are down to 0 DEG C and stirred 0.5 hour, are slowly added into 1- ethyls-(3- dimethylaminopropyls) phosphinylidyne two
Inferior amine salt hydrochlorate (EDC.HCL) (767mg, 4mmol), 4-N, N- lutidines (244mg, 2mmol), reacting liquid temperature is raised to
Reacted 24 hours at 60 DEG C.Reaction solution is cooled to room temperature, filtering, yield filtrate, is dried under reduced pressure removal solvent, remaining solid silicon
Glue-line analyses chromatographic separation and purification, and eluant, eluent is chloroform/methanol (9:Main Components 1v/v) are collected, are dried under reduced pressure to obtain breen
Solid powder formula (I) compound (0.40g, 18%).1H NMR(400MHz,CDCl3):δ 8.50 (s, 1H, Ar-H), 8.06-
8.15 (m, 3H, Ar-H, CH=CH), 7.70-7.83 (m, 2H, Ar-H), 7.38-7.49 (m, 1H, Ar-H), 7.57 (d, J=
8.4Hz, 4H, ArH), 7.55 (d, J=16.4Hz, 2H, CH=CH), 7.20 (s, 1H, Ar-H), 7.13 (d, J=8.4Hz, 2H,
), ArH 7.05 (d, J=8.4Hz, 2H, ArH), 6.98 (d, J=8.4Hz, 4H, ArH), 4.70-4.76 (m, 4H, CH2),
4.10-4.26(m,14H,CH2),3.55-3.78(m,24H,CH2),3.42-3.51(m,14H,CH2),3.24(s,3H,CH3),
2.34-2.55(m,10H,CH2),1.94-2.05(m,4H,CH2),1.47(s,3H,CH3),1.41(s,12H,CH3)。MS
(ESI):M/z=2183 [M+H]+。
Test case 1：The hydrolysis of formula (I) compound
Take formula (I) compound (218mg, 0.1mmol) to be dissolved in 50mL tetrahydrofurans, add 50mL pH 6.5PBS
Solution.It is 6.5 to keep solution ph, and reaction 24 hours is stirred at room temperature.Dichloromethane is added after being evaporated under reduced pressure out organic solvent
(200mL), concussion are stood, and collect organic phase.Organic phase anhydrous sodium sulfate drying, it is evaporated under reduced pressure, crude product silica gel column chromatography
Column separating purification, eluant, eluent are methylene chloride/methanol (20:1) red solid formula (II) compound (34mg, 30%) and brown, is obtained
Color solid formula (III) compound (18mg, 38%).
Formula (II) compound：1H NMR(400MHz,DMSO-d6)):δ 8.06 (d, J=16.4Hz, 2H, CH=CH), 7.57
(d, J=8.4Hz, 4H, ArH), 7.45 (d, J=16.4Hz, 2H, CH=CH), 7.33 (d, J=8.4Hz, 2H, ArH), 7.15
(d, J=8.4Hz, 2H, ArH), 7.02 (d, J=8.4Hz, 4H, ArH), 4.70-4.76 (m, 4H, CH2),4.16-4.20(m,
2H,CH2),3.76-3.78(m,2H,CH2),3.70-3.74(m,2H,CH2),3.66-3.68(m,2H,CH2),3.55-3.59
(m,2H,CH2),3.42-3.45(m,2H,CH2),3.24(s,3H,CH3),1.47(s,3H,CH3)；MS(ESI):M/z=1150
[M]+。
Formula (III) compound：1H NMR(400MHz,DMSO-d6):δ 9.50 (s, 1H, NH), 8.50 (s, 1H, Ar-H),
8.07-8.14 (m, 1H, Ar-H), 7.70-7.85 (m, 2H, Ar-H), 7.37-7.49 (m, 1H, Ar-H), 7.20 (s, 1H, Ar-
H),3.96-4.26(m,6H,CH2),3.55-3.72(m,4H,CH2),2.94-2.55(m,2H,CH2),2.34-2.45(m,4H,
CH2),1.94-2.05(m,2H,CH2)；MS(ESI):M/z=477 [M+H]+。
Test case 2：The photosensitive experiment of extracorporeal anti-tumor cell
Test sample：Formula (I) compound of the present invention, formula (II) compound and formula (III) compound
Test cell：Human lung carcinoma cell PC9
Main agents：1) DMEM complete culture solutions：Mould is added in 500mL DMEM liquid mediums (GIBCO companies)
Element/streptomysin 100,000 U, hyclone 56mL, mix.2) MTT solution (MTT：3- (4,5- dimethylthiazole -2) -2,5- hexichol
Base tetrazole bromide, it is purchased from MP companies of the U.S.)：Powdery MTT is dissolved in PBS solution with 5mg/mL concentration, filtration sterilization, now matched somebody with somebody
It is current.
Experimental method：
Test sample is made into the mother liquor that concentration is 1mM with DMSO；100 μ L1mg/mL mother liquor is taken during experiment, is added
1.15mL 0.5% (w/w) Emulsifier EL-60 pH 7.4PBS and pH 6.5PBS buffer solutions, are configured to 80 μ g/mL decoctions,
And the decoction of various concentrations is diluted to corresponding PBS, keep decoction pH value constant in dilution, drug solution preparing
Cell dosing culture is carried out after being stored at room temperature 24 hours afterwards.DMSO final concentration is≤1% in each medicine and negative control group.
From the attached tumor cells of exponential phase, after being digested with pancreatin, it is made into the DMEM culture mediums containing 10% hyclone suitable
The cell suspension of concentration is closed, is seeded in 96 well culture plates at 37 DEG C, 5%CO2Under the conditions of cultivate 24 hours.It is then respectively adding
Test medicine, solvent and each 100 μ L of nutrient solution of various concentrations, every group of 3 parallel holes.It is divided into illumination and lucifuge two after mixing
Group, dosing co-culture 2 hours after, discard culture medium, rejoin the culture medium without test sample or reference substance put 37 DEG C,
5%CO2Under the conditions of continue culture 24 hours.After 24 hours, 5mg/mL MTT, 20 μ L, 37 DEG C, 5%CO are added per hole2Under the conditions of
After being incubated 4 hours, supernatant is abandoned in suction, and 200 μ L DMSO are added per hole, is vibrated 10 minutes, ELIASA detection light absorption value, determines ripple
Long 570nm, excitation wavelength 630nm.Light source connects the optical filter that heat-insulated tank increased in 610nm by 200W Halogen lamp LED and carried
For light dosage is 48J cm-2。
Computational methods of the medicine to the inhibiting rate of growth of tumour cell：Growth of tumour cell inhibiting rate (%)=[(negative right
According to a group OD averages-administration group OD averages)/negative control group OD averages] × 100%.Half-inhibition concentration IC50Calculating, use
The logit Returns Law determine.
Experimental result：
The medicine of table 1 human lung carcinoma cell PC9 in irradiation IC50(nM) value
| Medicine | The decoction culture of cellular pH 7.4 | The decoction culture of cellular pH 6.5 |
| Formula (I) compound | >5000 | 45 |
| Formula (II) compound | 88 | 95 |
| Formula (III) compound | 85 | 78 |
Experimental result is shown, under light protected environment, the compound of all tests is not shown when at concentrations up to 5000nM
Cytotoxicity, but when irradiation situation formula (II) compound and formula (III) compound are in pH 6.5 and pH7.4 to human lung carcinoma cell
PC9 half lethal concentration IC50Value is between 78-95nM.But formula (I) compound is in pH 7.4 decoction culture cell, concentration
Up to 5000nM, there is no photosensitive activity completely in irradiation, but decoction of formula (I) compound in pH 6.5 carries out culture cell
When, show very high photosensitive activity, IC50It is worth for 45nM, this is due to that formula (I) compound hydrolysis obtains under the slightly sour environment of tumour
To high cell toxicity formula (II) compound and formula (III) compound.
It is known that slightly sour environment all be present in almost all of entity tumor, as lung cancer, stomach cancer, the cancer of the esophagus, breast cancer,
Carcinoma of urinary bladder, prostate cancer, cancer of pancreas, cholangiocarcinoma, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, incidence cancer, Eye tumor, uterine cancer and
There is slightly sour environment in the entity tumors such as oophoroma, compound disclosed in this patent or its pharmaceutically acceptable salt, or comprising
Its pharmaceutical composition can be prepared into photosensitive drug and treat above-mentioned cancer.
The foregoing is only embodiments of the invention, be not intended to limit the invention, it is all the present invention spirit and
All any modification, equivalent and improvement made within principle etc., should be included in the scope of the protection.
Claims (5)
- A kind of 1. compound shown in formula (I)：Or its pharmaceutically acceptable salt.
- 2. a kind of pharmaceutical composition, its contain therapeutically effective amount according to the compound shown in claim 1 and pharmaceutically Acceptable carrier.
- 3. light power is being prepared according to the compound shown in claim 1 or pharmaceutical composition according to claim 2 Purposes in medicine or photosensitive drug.
- 4. cancer is treated preparing according to the compound shown in claim 1 or pharmaceutical composition according to claim 2 Purposes in the medicine of disease.
- 5. purposes according to claim 4, wherein described cancer is selected from lung cancer, stomach cancer, the cancer of the esophagus, breast cancer, bladder Cancer, prostate cancer, cancer of pancreas, cholangiocarcinoma, the carcinoma of the rectum, colon cancer, cutaneum carcinoma, incidence cancer, Eye tumor, uterine cancer and ovary Cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710872025.4A CN107629077B (en) | 2017-09-25 | 2017-09-25 | The Gefitinib of acid-sensitive-two azole derivatives of fluorine boron and preparation method thereof and application in medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710872025.4A CN107629077B (en) | 2017-09-25 | 2017-09-25 | The Gefitinib of acid-sensitive-two azole derivatives of fluorine boron and preparation method thereof and application in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107629077A true CN107629077A (en) | 2018-01-26 |
| CN107629077B CN107629077B (en) | 2019-03-19 |
Family
ID=61102492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710872025.4A Active CN107629077B (en) | 2017-09-25 | 2017-09-25 | The Gefitinib of acid-sensitive-two azole derivatives of fluorine boron and preparation method thereof and application in medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107629077B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794518A (en) * | 2018-04-04 | 2018-11-13 | 安徽师范大学 | It is a kind of using BODIPY as organic conjugated molecule material of basic framework and preparation method thereof |
| CN111560033A (en) * | 2020-05-14 | 2020-08-21 | 遵义医科大学 | Synthesis method of light controlled release compound and application of light controlled release compound in tumor treatment |
| CN111978342A (en) * | 2020-09-10 | 2020-11-24 | 四川大学华西医院 | EGFR (epidermal growth factor receptor) -targeted fluorescence quenching probe as well as preparation method and application thereof |
| CN112920210A (en) * | 2021-02-01 | 2021-06-08 | 福州大学 | Red light activatable photodynamic therapy-chemotherapy combined prodrug and preparation and application thereof |
| CN115590958A (en) * | 2022-09-27 | 2023-01-13 | 中山大学（Cn） | Near infrared light/enzyme programmed activation supramolecular prodrug system and preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626781A (en) * | 2013-12-12 | 2014-03-12 | 福州大学 | Targeted anti-cancer molecule gefitinib phthalocyanine conjugate, and preparation and application thereof |
| CN106565760A (en) * | 2016-11-11 | 2017-04-19 | 深圳市声光动力生物医药科技有限公司 | BODIPY derivatives and preparation method thereof, and application of BODIPY derivatives to medicine |
-
2017
- 2017-09-25 CN CN201710872025.4A patent/CN107629077B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626781A (en) * | 2013-12-12 | 2014-03-12 | 福州大学 | Targeted anti-cancer molecule gefitinib phthalocyanine conjugate, and preparation and application thereof |
| CN106565760A (en) * | 2016-11-11 | 2017-04-19 | 深圳市声光动力生物医药科技有限公司 | BODIPY derivatives and preparation method thereof, and application of BODIPY derivatives to medicine |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794518A (en) * | 2018-04-04 | 2018-11-13 | 安徽师范大学 | It is a kind of using BODIPY as organic conjugated molecule material of basic framework and preparation method thereof |
| CN108794518B (en) * | 2018-04-04 | 2020-06-19 | 安徽师范大学 | Organic conjugated molecular material with BODIPY as basic skeleton and preparation method thereof |
| CN111560033A (en) * | 2020-05-14 | 2020-08-21 | 遵义医科大学 | Synthesis method of light controlled release compound and application of light controlled release compound in tumor treatment |
| CN111978342A (en) * | 2020-09-10 | 2020-11-24 | 四川大学华西医院 | EGFR (epidermal growth factor receptor) -targeted fluorescence quenching probe as well as preparation method and application thereof |
| CN111978342B (en) * | 2020-09-10 | 2021-04-13 | 四川大学华西医院 | EGFR (epidermal growth factor receptor) -targeted fluorescence quenching probe as well as preparation method and application thereof |
| CN112920210A (en) * | 2021-02-01 | 2021-06-08 | 福州大学 | Red light activatable photodynamic therapy-chemotherapy combined prodrug and preparation and application thereof |
| CN112920210B (en) * | 2021-02-01 | 2022-06-21 | 福州大学 | Red light activatable photodynamic therapy-chemotherapy combined prodrug and preparation and application thereof |
| CN115590958A (en) * | 2022-09-27 | 2023-01-13 | 中山大学（Cn） | Near infrared light/enzyme programmed activation supramolecular prodrug system and preparation method |
| CN115590958B (en) * | 2022-09-27 | 2023-12-01 | 中山大学 | Near infrared light/enzyme procedural activation supermolecule prodrug system and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107629077B (en) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107629077B (en) | The Gefitinib of acid-sensitive-two azole derivatives of fluorine boron and preparation method thereof and application in medicine | |
| CN106565760B (en) | Azole derivatives of fluorine boron two and preparation method thereof and application in medicine | |
| CN105461695B (en) | Pyrimidine or pyrrolotriazine derivatives and its production and use | |
| BR112018004175B1 (en) | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, HER2 INHIBITOR AND ANTITUMOR AGENT CONTAINING SAID COMPOUND AND THERAPEUTIC USES OF SAID COMPOUND | |
| CN106995437A (en) | Substituted indole or indazole pyrimidine derivatives and its production and use | |
| CN104974182B (en) | Silicon phthalocyanine compound, preparation method and its application in medicine | |
| CN106565763B (en) | Axial substituted silicon phthalocyanine complex sensitive pH and preparation method thereof and application in medicine | |
| CN106749478B (en) | 1,4 sensitive pH Di-substituted phthalocyanine Zn complexes and preparation method thereof and in application pharmaceutically | |
| CN111892580B (en) | 2-amino-4- (isoindoline-2-yl) pyrimidine-5-formamide derivative, preparation method and application | |
| CN108440583A (en) | A kind of new boronic acid derivatives and its pharmaceutical composition | |
| CN105037371A (en) | Deuterated indoleamine-2,3-dioxygenase inhibitor | |
| CN106957315B (en) | N- replaces benzenesulfonyl-azaindole oxybenzamide class compound and its prepares the purposes of drug | |
| CN107151236A (en) | A kind of 2,3- epoxies succinyl derivative and its production and use | |
| CN107629063B (en) | The Phthalocyanine Zinc of acid-sensitive-Gefitinib complex and preparation method thereof and application in medicine | |
| CN107098886A (en) | Quinazolinones PARP-1/2 inhibitor containing piperazinones and preparation method thereof, pharmaceutical composition and purposes | |
| CN107141284B (en) | Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage | |
| CN107556335B (en) | Boron Asia phthalocyanine-Gefitinib complex of acid-sensitive and preparation method thereof and application in medicine | |
| CN106892922A (en) | As the 5,8- dihydropteridine -6,7- derovatives of EGFR inhibitor and its application | |
| CN107474065B (en) | Gefitinib axial substituted phthalocyanine silicon complex of acid-sensitive and preparation method thereof and application in medicine | |
| CN114181144B (en) | Fluorobiphenyl methyl resorcinol ether derivative, preparation method and application thereof | |
| CN110981865B (en) | Medicine for treating brain glioma and preparation method thereof | |
| WO2019056376A1 (en) | Acid-sensitive gefitinib-fluoroboronbipyrrole derivative and preparation method therefor and medical use thereof | |
| WO2019056375A1 (en) | Acid-sensitive gefitinib axially substituted silicon phthalocyanine complex and preparation method therefor and medical use thereof | |
| WO2019056374A1 (en) | Acid-sensitive boron subphthalocyanine-gefitinib complex and preparation method therefor and medical use thereof | |
| CN103159649A (en) | Preparation of sulfonamides compounds and application of sulfonamides compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231107 Address after: No. 101, No. 12 Beihuan North Third Lane, Guantian Community, Shiyan Street, Bao'an District, Shenzhen City, Guangdong Province, 518000 Patentee after: SHENZHEN DAVOOS SCIENCE AND TECHNOLOGY LTD. Address before: D703, 7th Floor, Silver Star Technology Building, No. 1301, Sightseeing Road, Dabuxiang Community, Guanlan Street, Longhua District, Shenzhen City, Guangdong Province, 518000 Patentee before: SHENZHEN SONO-PHOTODYNAMIC BIO-MED TECHNOLOGY Ltd. |
|
| TR01 | Transfer of patent right |